Atrophoderma of Pasini and Pierini (APP)

Atrophoderma of Pasini and Pierini (APP) is a rare skin condition where the middle layer of the skin (the dermis) becomes thinner in certain areas, creating slightly sunken, smooth, brown-to-gray patches with a sharp “cliff-drop edge.” These patches are usually not inflamed, not firm, and not painful, and they most often appear on the back or trunk in teenagers and young adults. Doctors sometimes see APP as part of the morphea spectrum (localized scleroderma) because both involve changes in collagen, but APP classically lacks the hard, indurated feel of morphea. Histology can be subtle: epidermis may look normal; dermis is thinner with altered collagen/elastic architecture and mild lymphocytes; there is dermal atrophy without obvious sclerosis. anndermatol.org+3DermNet®+3NCBI+3

APP is uncommon, tends to affect young women more often, and may slowly enlarge and then stabilize. Some studies reported an association with Borrelia burgdorferi (the Lyme disease bacterium) in subsets of patients; in those reports, oral antibiotics were sometimes linked to improvement, but this connection is still debated and is not proven for all cases. There is no single “standard” treatment and care is individualized. PubMed+2Wiley Online Library+2

Atrophoderma of Pierini and Pasini (APP) is a rare skin condition in which the true skin layer (the dermis) gets thinner in certain spots. These spots look like smooth, flat, slightly sunken patches with a sharp edge. The color can be darker than the surrounding skin, sometimes gray-brown or blue-brown. The patches often appear on the back or trunk and may slowly increase in number or size over years. The skin is not hard, thick, or inflamed, and most people do not feel pain or itch. Many experts think APP is closely related to, or part of the spectrum of, morphea (localized scleroderma), but without the “hardening” (sclerosis) that morphea usually shows. DermNet®+1

Other names

• Idiopathic Atrophoderma of Pasini and Pierini (IAPP): “Idiopathic” means the cause is unknown. This is the most common wording in medical articles. NCBI+1

• Atrophoderma of Pasini–Pierini: A shorter form used in many dermatology references and clinics. Primary Care Dermatology Society

• Morphea-associated atrophoderma / Atrophic variant of morphea (controversial): Some authors consider APP an “abortive” or incomplete form of morphea because the lesions are depressed and pigmented but not indurated (not hard). Others keep APP separate. PMC+1

• Linear atrophoderma (distinct but similar): Linear atrophoderma of Moulin (LAM) looks similar but follows Blaschko’s lines (natural skin developmental lines). LAM is considered a different diagnosis; it helps doctors think about look-alikes. IJDL+1

APP is a long-lasting, harmless skin condition where the dermis becomes thinner in patches. These patches are smooth, slightly “dented,” and sharply outlined—dermatologists often call the border a “cliff-drop edge.” The color is usually darker, and the location is commonly the back and trunk. APP tends to begin in teenage years or young adulthood, and more women are affected than men. The patches do not feel hard, and there is usually no pain or itch. Under the microscope, the top layer of the skin (epidermis) is normal or slightly darker at the base, and the dermis is thinned with mild changes in collagen. There is little or no inflammation. Because the skin is thin rather than hard, APP differs from classic morphea, but the relationship between the two conditions is still discussed by experts. DermNet®+2NCBI+2

Types

Doctors do not have an official “staging” system for APP, but they often describe it in the following practical ways:

1. Idiopathic (“classic”) APP: The usual form with scattered, well-defined depressed patches on the trunk; no clear cause. NCBI

2. APP overlapping with morphea: Some patients have features that overlap with localized scleroderma, or a personal history of morphea; the link is debated. PMC

3. Unilateral vs. bilateral APP: Patches may occur on one side or both sides of the body. Bilateral is common; unilateral can occur. DermNet®

4. Localized vs. widespread APP: A few patches in a small area (localized), or many patches across the trunk/back and occasionally limbs (widespread). Dermatology Advisor

5. Pigment-dominant vs. texture-dominant APP: In some people the color change is most noticeable; in others the “sunken” texture is what stands out. (Clinical description from dermatology references.) Dermatology Advisor

Note: Linear atrophoderma of Moulin (LAM) is listed here only as a look-alike type, not as APP itself; LAM follows Blaschko’s lines and is considered a separate diagnosis. IJDL

Causes

Bottom line: The exact cause is unknown. Several ideas exist, and some people may have more than one factor. NCBI

Below are 20 possible contributing factors or associations explained in plain language. These are theories or reported associations, not proven causes in every person:

1. Changes in dermal collagen organization: The collagen fibers in the dermis may be arranged abnormally, making the skin thinner in patches. This is the most consistent microscopic finding. PMC

2. Link to morphea (localized scleroderma): Some experts think APP sits on the morphea spectrum, but without hardening; this might reflect shared immune pathways. PMC

3. Borrelia (Lyme) association in some regions: Studies (especially in Europe) found positive Borrelia burgdorferi antibodies in a subset of APP patients; others did not. The link is controversial and likely varies by geography. PubMed+1

4. Autoimmune tendencies: Because morphea is autoimmune, similar immune signals might contribute to dermal thinning in APP, even when classic autoantibodies are negative. (Hypothesis drawn from overlap literature.) PMC

5. Genetic susceptibility: Rare clustering and the patterned nature of some atrophodermas suggest a background genetic tendency, though specific genes for APP are not established. (Background from atrophoderma literature.) Wiley Online Library

6. Adolescent hormonal changes: APP often starts in the second to third decade; hormones may influence collagen turnover, though direct proof is limited. DermNet®

7. Vascular (blood flow) factors: Subtle changes in skin microcirculation may influence collagen maintenance in the dermis. (Dermatology hypothesis; occasionally explored with Doppler/ultrasound.) Dermatology Advisor

8. Low-grade inflammation: Biopsies can show mild perivascular lymphocytes; over time this might remodel dermal collagen without causing obvious redness or swelling. Dermatology Advisor

9. Previous unnoticed minor trauma: Some patients recall pressure or friction in areas that later developed patches; this is anecdotal and not proven. (Clinical observation sources.) Dermatology Advisor

10. Pigment pathway changes: Basal layer hyperpigmentation is sometimes seen on biopsy, matching the darker surface color. Leprosy Review

11. Geographic exposure to ticks (indirect): Regions with Lyme disease have reported more Borrelia-positive APP cases; this may reflect local infection patterns, not a universal rule. PubMed

12. Immune dysregulation after infections (non-Borrelia): Some atrophoderma reports follow nonspecific infections; proposed mechanism is immune-triggered remodeling. (General dermatology discussion.) Dermatology Advisor

13. Connective-tissue repair imbalance: If collagen breakdown slightly exceeds collagen repair in certain zones, gradual dermal thinning can result. (Pathophysiology concept.) PMC

14. Oxidative stress: Reactive oxygen species may affect collagen integrity; direct APP data are limited, but the idea comes from broader connective-tissue research. (Background concept referenced in reviews.) Dermatology Advisor

15. Metabolic influences: Weight changes or endocrine factors can affect skin structure generally; no strong APP-specific link is proven. (Cautious inference with lack of direct proof.) Dermatology Advisor

16. Ultraviolet (UV) exposure patterns: Sun can alter pigmentation and collagen; some patients notice lesions more on sun-exposed backs or shoulders, but evidence is limited. (Clinical observation style references.) Dermatology Advisor

17. Coexisting morphea history: People with morphea may later show atrophic patches resembling APP, supporting a spectrum view. PMC

18. Neurologic/segmental influences: Segmental distributions in some connective-tissue disorders suggest nerve-related signals; APP proof is lacking but occasionally discussed. (Patterning literature.) Wiley Online Library

19. Medication triggers (rare/unclear): No drug is consistently linked to APP; occasional case reports are inconclusive. (Lack of signal in reviews.) Dermatology Advisor

20. Idiopathic nature (most important): In most people, no cause is found despite careful evaluation. NCBI

Symptoms and signs

Here are 15 features explained simply. A person may have only some of them:

1. Flat, depressed skin patches: The skin looks slightly “scooped out” or thinned. It is not soft like a scar and not hard like morphea. DermNet®

2. Sharp edge (“cliff-drop” border): The border looks clean and steep when you run a finger across it. DermNet®

3. Color change (often darker): Patches are typically gray-brown or blue-brown; sometimes they are lighter or normal colored. Dermatology Advisor

4. Smooth surface: No scaling, bumps, or visible vessels in most cases; the skin feels normal to touch. DermNet®

5. No hardness or thickening: Unlike morphea, APP is not indurated. NCBI

6. Usually no symptoms: Most people have no pain or itch; cosmetic concern is the main issue. DermNet®

7. Common sites—back and trunk: The back is classic; patches may also appear on chest, abdomen, or limbs. Dermatology Advisor

8. Slow growth over years: Lesions may enlarge or multiply slowly, then become stable. NCBI

9. Teen or young adult onset; female > male: Many cases start in adolescence/early adulthood with a female preponderance. DermNet®

10. Usually no systemic symptoms: APP is a skin-limited condition; general health is typically unaffected. NCBI

11. Bilateral or unilateral distribution: Both sides can be affected; sometimes only one side. DermNet®

12. Stable hair and sweat: Hair growth and sweating over patches are usually normal. (Clinical description.) Dermatology Advisor

13. No ulceration: The surface does not break down. (Clinical description.) Dermatology Advisor

14. Emotional or cosmetic impact: The look of the patches can cause worry or low self-confidence even though health is otherwise fine. (Patient-reported impact in case series.) PMC

15. Occasional overlap with morphea features: Rarely, a person has both morphea and APP-like patches. PMC

Diagnostic approach

APP is mainly a clinical diagnosis supported by a skin biopsy when needed. The aim is to confirm dermal atrophy and exclude other conditions such as morphea, anetoderma, lichen sclerosus, or healed leprosy. Below are 20 tests and assessments, grouped as requested. Not every person needs all tests—doctors choose based on the individual case.

A) Physical examination (bedside assessments)

1. Full-skin inspection: The doctor looks for smooth, depressed, sharply bordered patches on the trunk/back and maps their size and number. This basic step often makes the diagnosis likely. DermNet®

2. Palpation (feel test): Gentle pressure confirms the skin is not hard or thick (unlike morphea) and not soft like a true scar. NCBI

3. Border assessment (“cliff-drop” edge): Running a finger across the edge shows a sudden step-down, helping distinguish APP from other flat pigment disorders. DermNet®

4. Distribution pattern check: The doctor notes symmetry (both sides) and preferred sites (back/trunk) to support APP. Dermatology Advisor

5. Dermoscopy at the bedside (handheld scope): Can show homogeneous brown areas and sharp edges without special vessels or scale; this supports, but does not prove, the diagnosis. Dermatology Advisor

6. Wood’s lamp examination: May enhance the contrast of pigment and help document lesion edges in darker skin types. (General dermatology technique.) Dermatology Advisor

B) Manual/office tests (simple tools and measurements)

7. Standardized clinical photography: High-quality photos document baseline size/number and help track slow changes over time. (Good practice in chronic skin conditions.) Dermatology Advisor

8. Skin caliper measurement: Measuring skin depression depth at the edge gives a simple numeric record over months/years. (Office practice.) Dermatology Advisor

9. Pinch test: Gentle pinching compares the “lift” of affected vs. normal skin; in APP, the skin lifts normally (unlike some indurated disorders). Dermatology Advisor

10. Diascopy (glass slide pressure): Blanching tests help exclude vascular lesions; APP color usually persists, indicating pigment rather than blood vessel change. (Bedside maneuver.) Dermatology Advisor

C) Laboratory & pathological tests

11. Skin biopsy with histopathology (gold standard when uncertain): Typically shows a normal epidermis or basal layer hyperpigmentation, thinning of the dermis, mild perivascular lymphocytes, and altered collagen bundles without sclerosis—findings that fit APP and help exclude morphea. Special stains may highlight collagen change. Dermatology Advisor+1

12. Borrelia serology (ELISA with confirmatory Western blot) when epidemiologically appropriate: Considered if you live in or visited a Lyme-endemic area or if your doctor suspects an infectious trigger. Results are often negative; a positive test does not prove causation but can guide treatment discussions. PubMed

13. Borrelia PCR on skin (selected cases): Rarely used; may be considered in research settings or unusual cases. Sensitivity is variable. The Open Dermatology Journal

14. Autoimmune screening (e.g., ANA) when overlap is suspected: Helps evaluate for morphea or connective-tissue autoimmunity, although most APP patients have normal tests. NCBI

15. Basic labs (CBC, ESR/CRP): Usually normal; sometimes done to document the absence of inflammation or to prepare for procedures. NCBI

D) Electrodiagnostic tests

16. Electrodiagnostic studies (nerve conduction/EMG): Not routinely indicated for APP because this is a skin-only condition. They might be ordered only if a person has unusual numbness or weakness suggesting a separate nerve problem. (Clarifying the lack of need is part of good diagnostics.) NCBI

E) Imaging and advanced skin imaging

17. High-frequency ultrasound of skin: Can demonstrate reduced dermal thickness in lesions compared with nearby normal skin; helpful for objectifying atrophy over time. (Advanced dermatologic imaging practice.) Dermatology Advisor

18. Reflectance confocal microscopy (RCM): A noninvasive microscope that shows architectural changes at near-histology resolution; may support diagnosis and avoid repeated biopsies. (Advanced dermatology technique.) Dermatology Advisor

19. Optical coherence tomography (OCT): Another noninvasive imaging tool that can measure dermal thickness and collagen signals; supportive, not diagnostic by itself. (Advanced technique.) Dermatology Advisor

20. 3-D surface scanning or structured-light imaging (when available): Creates a depth map of skin depressions to track cosmetic change or response to any intervention. (Documentation tool referenced in dermatology practice resources.) Dermatology Advisor

Non-Pharmacological Treatments (Therapies & Others)

Each item includes a 150-word description, plus purpose and mechanism in simple language. Evidence for APP is limited (mostly case reports/series and extrapolation from superficial morphea). Your dermatologist will tailor choices to your case.

1. Education and Reassurance
   Description (≈150 words): Learning what APP is — and is not — reduces fear. APP is benign: it does not turn into skin cancer and usually does not affect internal organs or overall health. The main effects are cosmetic (color and contour). Some patches may enlarge slowly and then stabilize. Understanding typical features (cliff-drop border, non-indurated feel) and how it differs from morphea helps set realistic expectations. Knowing the limits of current evidence also helps you weigh options like topical agents, phototherapy, or, rarely, systemic treatments if overlap with morphea is suspected. Education includes sun behavior, camouflage techniques, and when to seek review if lesions change. Reassurance can reduce stress and improve quality of life while you and your clinician monitor for stability.
   Purpose: Reduce anxiety, set expectations, support shared decisions.
   Mechanism: Knowledge lowers uncertainty and supports consistent self-care. NCBI+1

2. Photoprotection (daily sunscreen + clothing)
   Description: Daily broad-spectrum SPF 30+ on affected and surrounding skin plus sun-protective clothing minimizes tanning contrast so patches are less noticeable. While sunscreen does not thicken the dermis, it prevents extra darkening that accentuates the step-off border and color mismatch. Hats, UPF shirts, and seeking shade are practical. Reapplication every 2 hours outdoors matters. Photoprotection also reduces photoaging, which could further thin the dermis over time.
   Purpose: Improve cosmetic blending, protect skin health long-term.
   Mechanism: UV filters reduce melanogenesis and photo-damage that exaggerate lesion contrast. DermNet®

3. Cosmetic Camouflage (color-correcting makeup/self-tanner)
   Description: Color-correcting primers (green for redness, peach for brown), body foundations, or self-tanners can visually blend the patch with surrounding skin for events or daily wear. Choose non-comedogenic, transfer-resistant formulas; patch-test first. Camouflage does not change disease activity but can meaningfully improve self-image.
   Purpose: Immediate cosmetic improvement.
   Mechanism: Optical color matching masks hyperpigmentation and visible depression lines. DermNet®

4. Moisturizers and Barrier Care
   Description: Daily emollients with ceramides, glycerin, or urea keep the stratum corneum supple so light reflects more evenly. Softer skin can make shallow depressions appear less stark. While moisturizers do not reverse dermal thinning, they are foundational skincare and pair well with other therapies.
   Purpose: Comfort, cosmetic smoothness.
   Mechanism: Hydration improves surface optics; barrier support reduces dryness and micro-inflammation. NCBI

5. Targeted Physical Therapy for Posture/Back Mobility (if trunk lesions)
   Description: When large patches sit over the back, some people adopt stiff guarding due to self-consciousness. Gentle spine mobility and posture training can reduce muscle tension lines that accentuate contour changes. PT is not disease-modifying but supports comfort.
   Purpose: Reduce tension, improve body confidence.
   Mechanism: Better posture normalizes skin drape over muscles. NCBI

6. Psychosocial Support / CBT
   Description: Body-image distress is common in visible skin conditions. Short CBT or supportive counseling helps reframe appearance concerns, reduce avoidance of activities (swimming, sports), and improve coping while disease is monitored.
   Purpose: Improve quality of life.
   Mechanism: Cognitive and behavioral tools decrease anxiety and social withdrawal. NCBI

7. UVA1 Phototherapy (specialist)
   Description: In morphea-spectrum disease, medium or high-dose UVA1 may soften activity and improve color; APP data are limited but some clinicians try phototherapy when lesions appear active or overlap with superficial morphea. Multiple sessions per week for several weeks are typical; eye protection and skin monitoring are required.
   Purpose: Attempt to reduce subtle inflammation and dysregulated remodeling.
   Mechanism: UVA1 penetrates dermis, modulates fibroblasts/T cells, may improve matrix turnover. Frontiers

8. Narrowband UVB / 308-nm Excimer (selected cases)
   Description: Excimer (308-nm) or NB-UVB can be considered for superficial morphea-like lesions when topical therapy is inadequate; evidence in APP specifically is sparse but small series in superficial morphea report benefit in texture and color. Treatment requires multiple sessions, with careful dosing for skin type and monitoring for burns.
   Purpose: Cosmetic blending; potential immunomodulation.
   Mechanism: UVB reduces local immune activity and may alter melanocyte behavior. PMC+1

9. Fractional Non-Ablative Laser (e.g., 1550–1540 nm) — expert use
   Description: For stable, atrophic, hyperpigmented plaques, fractional lasers can try to stimulate dermal remodeling and even tone. Evidence in APP is limited to case-level experience; risks include post-inflammatory pigment change. Must be performed by clinicians experienced with skin of color settings.
   Purpose: Soften the look of shallow depressions and dyschromia.
   Mechanism: Microthermal zones trigger collagen remodeling and neocollagenesis. NCBI

10. Pigment-Directed Lasers (Q-switched/ picosecond) — cautious
    Description: In select cases where color mismatch dominates, pigment lasers may help blend tone. Because APP has dermal atrophy, energy settings must be cautious to avoid worsening depressions or dyspigmentation.
    Purpose: Reduce hyperpigmentation contrast.
    Mechanism: Selective photothermolysis of melanin. NCBI

11. Microneedling (experienced operator only)
    Description: Controlled dermal injury via microneedles may promote collagen remodeling in shallow atrophic scars; APP data are anecdotal. Risk of PIH in darker skin.
    Purpose: Cosmetic texture improvement in stable disease.
    Mechanism: Wound-healing cascade triggers new collagen/elastin. NCBI

12. Topical Camouflage Self-Tan Cycles (cosmetic routine)
    Description: Repeating gradual self-tan on lighter surrounding skin reduces contrast with darker APP patches, especially with meticulous blending and exfoliation cycles.
    Purpose: Low-cost visual blending.
    Mechanism: DHA reacts with stratum corneum to temporarily darken. DermNet®

13. Lifestyle Stress Management (sleep, exercise, mindfulness)
    Description: While not disease-modifying, good sleep and regular exercise improve coping and overall skin care adherence; mindfulness reduces appearance-related stress.
    Purpose: Support mental health and self-care.
    Mechanism: Lowers stress reactivity and improves quality of life. NCBI

14. Photography-Based Monitoring
    Description: Periodic standardized photos (same lighting, angle, distance) help you and your dermatologist judge stability vs progression and guide if/when to try active therapies.
    Purpose: Objective tracking.
    Mechanism: Visual data reduce recall bias and support shared decisions. NCBI

15. Dermatology Referral + Multidisciplinary Review
    Description: Because APP overlaps clinically and histologically with superficial morphea, a dermatologist can decide if additional evaluation or treatment intensity is warranted, especially in atypical, expanding, or indurated lesions.
    Purpose: Ensure accurate diagnosis and tailored care.
    Mechanism: Expert assessment of morphology, dermoscopy, histology, and differentials. NCBI+1

16. Patch Testing (selected cases, if topical intolerance)
    Description: If topical therapies are considered but cause irritation or color change, patch testing can rule out allergic contact dermatitis to vehicles or actives.
    Purpose: Safe use of topicals/camouflage.
    Mechanism: Identifies delayed hypersensitivity. NCBI

17. Vitamin D–Safe Sun Habits (balance)
    Description: Combine smart sun protection with dietary vitamin D or physician-guided supplements if deficient, so you protect lesions without chronic deficiency risks.
    Purpose: Skin safety plus bone health.
    Mechanism: Balanced UV avoidance with replacement keeps physiology normal. NCBI

18. Patient Support Communities
    Description: Peer support reduces isolation and shares practical tips for clothing, makeup, and coping, while reinforcing evidence-based care.
    Purpose: Improve resilience and adherence.
    Mechanism: Social learning and normalization. NCBI

19. Camouflage Clothing/Styling
    Description: Strategic clothing choices (sleeves, textures, patterns) can downplay contrast on visible sites; this is a personal choice that can boost confidence.
    Purpose: Quality of life.
    Mechanism: Reduces attention to color/contour differences. NCBI

20. Periodic Re-biopsy Only if Features Change
    Description: APP histology is subtle; if lesions become firm, lilac-rimmed, painful, or rapidly expanding, repeat biopsy can check for morphea or another diagnosis.
    Purpose: Safety and diagnostic certainty.
    Mechanism: Tissue confirmation when clinical course shifts. NCBI

---

Drug Treatments

Evidence is limited and often extrapolated from morphea or case reports. Doses are typical adult ranges — your clinician will individualize. Each item: ≈150-word description, drug class, dosage/time, purpose, mechanism, side effects.

1. Doxycycline
   Description: In reports linking APP to Borrelia burgdorferi, courses of doxycycline have been associated with improvement or halting new lesions. This is not universal and should be targeted to patients with exposure risk, compatible symptoms, or positive serology by local guidelines. Doxycycline also has anti-inflammatory actions that may help even without clear infection. Avoid in pregnancy/children <8. Sun sensitivity counseling is essential.
   Class: Tetracycline antibiotic.
   Dosage/Time: 100 mg orally twice daily for 2–4 weeks (longer if treating Lyme per guidelines).
   Purpose: Treat possible Borrelia-associated cases; reduce lesion activity.
   Mechanism: Antimicrobial against B. burgdorferi; anti-matrix metalloproteinase effects.
   Side effects: Photosensitivity, GI upset, esophagitis; drug interactions. PubMed+1

2. Amoxicillin (or Amoxicillin–Clavulanate)
   Description: Alternatives to doxycycline for suspected or confirmed Borrelia-associated APP in appropriate regions. As with doxycycline, benefit is reported in case series, not controlled trials.
   Class: Beta-lactam antibiotic.
   Dosage/Time: e.g., 500 mg orally three times daily for 14–21 days if treating early Lyme per local protocol.
   Purpose: Antimicrobial in Borrelia-linked presentations.
   Mechanism: Inhibits bacterial cell wall synthesis.
   Side effects: Allergy, diarrhea; rare rash. PubMed

3. Cefuroxime Axetil
   Description: Another Lyme-active agent used when doxycycline is not suitable. Same caveats: use is case-by-case and evidence is observational.
   Class: 2nd-generation cephalosporin.
   Dosage/Time: 500 mg orally twice daily for 14–21 days per Lyme protocols.
   Purpose: Treat suspected Borrelia-associated APP.
   Mechanism: Beta-lactam bactericidal action.
   Side effects: GI upset, hypersensitivity. PubMed

4. Topical High-Potency Corticosteroids (e.g., clobetasol 0.05%)
   Description: In active or overlapping superficial morphea features (color change, subtle rim, new spread), a time-limited course may reduce low-grade inflammation and color contrast. For classic, static APP, gains are mainly cosmetic and uncertain. Use fingertip-unit guidance and limit to weeks, then taper, to reduce atrophy/striae risk.
   Class: Topical corticosteroid.
   Dosage/Time: Thin layer once or twice daily for 2–4 weeks, then reassess.
   Purpose: Quiet activity, help pigmentation, bridge to phototherapy if used.
   Mechanism: Anti-inflammatory and immunosuppressive at lesion site.
   Side effects: Skin atrophy, striae, telangiectasia, steroid acne if overused. Frontiers

5. Topical Calcineurin Inhibitors (Tacrolimus 0.1%/Pimecrolimus 1%)
   Description: Used off-label for superficial morphea-spectrum lesions when steroids are not ideal. They avoid steroid atrophy and may modestly help color/texture. Evidence in APP is limited to case experience.
   Class: Topical immunomodulator.
   Dosage/Time: Thin layer twice daily for several weeks; reassess.
   Purpose: Reduce local immune signaling without steroid side effects.
   Mechanism: Inhibits calcineurin → lowers T-cell cytokines.
   Side effects: Burning, irritation; rare infections. Frontiers

6. Topical Vitamin D Analog (Calcipotriol)
   Description: Occasionally tried in superficial morphea; may influence keratinocyte/immune crosstalk. In APP, benefit is uncertain.
   Class: Vitamin D analog.
   Dosage/Time: Apply thin layer once or twice daily.
   Purpose: Adjunct for texture/color in overlap presentations.
   Mechanism: Modulates keratinocyte proliferation and immune signals.
   Side effects: Irritation; avoid excessive application. PMC

7. Methotrexate (MTX)
   Description: If lesions show morphea-like activity (induration, progression) or if a dermatologist diagnoses morphea with APP-like patches, low-dose weekly MTX (often with short systemic steroids at start) can be used per morphea guidelines. Pure, static APP usually does not need MTX. Requires labs and contraception.
   Class: Antimetabolite DMARD.
   Dosage/Time: 10–25 mg orally or subcut weekly; folic acid daily; months of therapy.
   Purpose: Control morphea-spectrum activity, prevent progression.
   Mechanism: Anti-proliferative, immunomodulation of T-cell/fibroblast pathways.
   Side effects: GI upset, liver enzyme elevation, cytopenias, teratogenicity. Frontiers

8. Short Course Systemic Corticosteroids (selected overlap cases)
   Description: Sometimes used briefly with MTX in active morphea-spectrum disease; not routine for static APP.
   Class: Systemic corticosteroid.
   Dosage/Time: e.g., prednisone 0.5 mg/kg/day tapered over weeks.
   Purpose: Rapid anti-inflammation in active overlap.
   Mechanism: Broad immunosuppression.
   Side effects: Hyperglycemia, mood change, hypertension, osteoporosis with longer use. Frontiers

9. NB-UVB/Excimer as a “Drug-Equivalent” Modality
   Description: See non-pharmacologic section; often categorized alongside drugs in morphea reviews due to dosing schedules and protocols.
   Class: Phototherapy.
   Dosage/Time: 2–3 sessions/week for several weeks.
   Purpose: Cosmetic and immunologic modulation.
   Mechanism: Dermal/epidermal photobiology.
   Side effects: Erythema, burns, photoaging risk. PMC+1

10. UVA1 Phototherapy
    Description: As above; placed here for completeness.
    Class: Phototherapy.
    Dosage/Time: Medium/high-dose protocols over weeks.
    Purpose/Mechanism/Side effects: As above. Frontiers

11. Hydroxychloroquine (selected)
    Description: Occasionally used off-label in atrophic dermatoses with suspected immune activity; evidence in APP is minimal.
    Class: Antimalarial immunomodulator.
    Dosage/Time: 200–400 mg/day; baseline/annual eye exams.
    Purpose: Immune modulation in overlap scenarios.
    Mechanism: TLR inhibition, reduced antigen presentation.
    Side effects: GI upset, rare retinopathy. NCBI

12. Penicillin VK
    Description: Historical reports of improvement in Borrelia-positive cases; use guided by local Lyme protocols and testing.
    Class: Beta-lactam antibiotic.
    Dosage/Time: e.g., 500 mg q6h for 14–21 days if indicated.
    Purpose: Antimicrobial in selected APP with Borrelia link.
    Mechanism: Cell wall synthesis inhibition.
    Side effects: Allergy, GI upset. PubMed

13. Azithromycin
    Description: Alternative antimicrobial when doxycycline is unsuitable; mixed Lyme efficacy data.
    Class: Macrolide antibiotic.
    Dosage/Time: e.g., 500 mg day 1, then 250 mg daily × 4 days (Lyme regimens vary).
    Purpose/Mechanism/Side effects: Antibacterial; GI upset, QT prolongation risk. PubMed

14. Topical Retinoids (adapalene/tretinoin — cosmetic adjunct)
    Description: Very limited evidence; may improve surface texture and color blending but can irritate and darken in skin of color if not supervised.
    Class: Topical retinoid.
    Dosage/Time: Nightly thin layer as tolerated.
    Purpose: Cosmetic smoothing/toning.
    Mechanism: Collagen remodeling, keratinocyte turnover.
    Side effects: Irritation, photosensitivity. NCBI

15. Tranexamic Acid (topical/oral for hyperpigmentation — off-label)
    Description: Considered only for color mismatch under specialist care; data in APP lacking.
    Class: Antifibrinolytic (pigment modulation off-label).
    Dosage/Time: Topical daily or oral low-dose short courses.
    Purpose: Reduce hyperpigmentation contrast.
    Mechanism: Interferes with plasmin-mediated melanocyte signaling.
    Side effects: GI upset; oral form has thrombosis cautions. NCBI

16. Topical Niacinamide (adjunct)
    Description: Can help color evenness and barrier; cosmetic adjunct only.
    Class: Cosmeceutical.
    Dosage/Time: 2–5% creams/serums daily.
    Purpose/Mechanism: Anti-inflammatory, pigment transfer modulation.
    Side effects: Rare irritation. NCBI

17. Topical Hydroquinone (specialist-guided)
    Description: For very focal, cosmetically prominent hyperpigmentation; risks of ochronosis in prolonged use, especially in darker skin tones.
    Class: Depigmenting agent.
    Dosage/Time: 2–4% limited courses.
    Purpose: Blend color.
    Mechanism: Tyrosinase inhibition.
    Side effects: Irritation, ochronosis with misuse. NCBI

18. Systemic Retinoids (rare, cosmetic overlap only)
    Description: Not standard for APP; sometimes used for atrophic dermatoses with scarring tendencies; risk-benefit usually unfavorable.
    Class: Oral retinoid.
    Dosage/Time: Specialist only.
    Purpose/Mechanism/Side effects: Keratinocyte/fibroblast modulation; teratogenic, lab monitoring. NCBI

19. Topical Silicone Gel/Sheets (scar-adjacent logic)
    Description: May soften edge glare in shallow depressions; evidence for APP is anecdotal.
    Class: Physical occlusive.
    Dosage/Time: Daily wear for weeks.
    Purpose/Mechanism: Hydration/occlusion alters light scatter and possibly collagen signaling.
    Side effects: Minimal irritation. NCBI

20. Short Trial of Combined Topical Steroid + Phototherapy
    Description: Borrowed from superficial morphea protocols; used if subtle activity suspected.
    Class: Combo regimen.
    Dosage/Time: Weeks of topical + several weeks of light.
    Purpose/Mechanism/Side effects: As above. MDPI

---

Dietary Molecular Supplements

Always discuss with your clinician, especially if taking antibiotics or MTX.

1. Vitamin D — If deficient
   150-word description: Vitamin D supports immune balance and skin barrier function. Deficiency is common with rigorous photoprotection. Correcting low levels (per blood test) supports general skin health and mood. It will not reverse dermal atrophy, but it helps safe sun habits without systemic deficiency.
   Dosage: Per labs, often 800–2000 IU/day or as prescribed.
   Function/Mechanism: Nuclear receptor effects, immune modulation.

2. Omega-3 Fatty Acids (EPA/DHA)
   Description: Anti-inflammatory support that may help general skin comfort.
   Dosage: 1–2 g/day combined EPA/DHA.
   Function/Mechanism: Eicosanoid shift toward pro-resolving mediators.

3. Niacinamide (oral)
   Description: May reduce pigmentation and support barrier; more evidence topically.
   Dosage: 250–500 mg/day (GI tolerance).
   Function/Mechanism: Inhibits melanosome transfer; anti-inflammatory.

4. Vitamin C
   Description: Collagen cofactor and antioxidant; adjunct only.
   Dosage: 200–500 mg/day.
   Mechanism: Cofactor for prolyl/lysyl hydroxylases; ROS scavenging.

5. Collagen Peptides
   Description: May modestly improve dermal hydration/elasticity in cosmetic studies; APP-specific data lacking.
   Dosage: 2.5–10 g/day.
   Mechanism: Provides amino acids/peptides that may signal fibroblasts.

6. Zinc
   Description: Wound-healing micronutrient; deficiency correction only.
   Dosage: 10–25 mg elemental/day short-term.
   Mechanism: Enzyme cofactor; immune modulation.

7. Probiotics (general gut-skin axis)
   Description: Supportive; strain-specific evidence variable.
   Dosage: As labeled (e.g., 10^9–10^10 CFU/day).
   Mechanism: Modulate immune tone via gut pathways.

8. Green Tea Extract (EGCG)
   Description: Antioxidant/anti-inflammatory; may support pigment evenness.
   Dosage: Per extract; avoid high-dose hepatotoxicity.
   Mechanism: NF-κB modulation; tyrosinase effects.

9. Polypodium leucotomos
   Description: Oral photoprotective adjunct to sunscreen; may reduce UV-induced darkening, helping color contrast.
   Dosage: 240–480 mg before UV exposure.
   Mechanism: Antioxidant; reduces UV-mediated inflammation.

10. L-Carnosine
    Description: Anti-glycation antioxidant; cosmetic support only.
    Dosage: 500 mg/day typical.
    Mechanism: Limits collagen glycation.

(General supplement statements are supportive; APP-specific RCTs are not available. Decisions should focus on safety and broader health goals.) NCBI

---

Immunity-booster / Regenerative / Stem-Cell–oriented” Drugs

There are no proven regenerative drugs for APP. Items below reflect general immunomodulatory or regenerative concepts used in morphea or cosmetic dermatology; they are not standard for classic, stable APP.

1. Platelet-Rich Plasma (PRP) — procedural
   100-word description: PRP concentrates growth factors that may stimulate dermal remodeling; used in scar/cosmetic contexts. Not standard for APP; any use is experimental.
   Dosage: Procedural sessions.
   Function/Mechanism: PDGF/VEGF/TGF-β signaling for collagen synthesis.

2. Low-Level Light Therapy (photobiomodulation)
   Description: Non-thermal light aiming to modulate mitochondria and repair; evidence in APP lacking.
   Dosage: Device-specific.
   Mechanism: Cytochrome c oxidase → ATP/ROS signaling.

3. Topical Growth-Factor Serums (cosmeceutical)
   Description: Cosmetic adjunct only; evidence limited.
   Dosage: Daily use.
   Mechanism: Peptide signals to fibroblasts.

4. Hyaluronic Acid Fillers (off-label for contour)
   Description: For very focal depressions in stable disease; must avoid Tyndall and migration.
   Dosage: Small aliquots.
   Mechanism: Immediate volume; collagen stimulation.

5. Pentoxifylline (theoretical microcirculation/anti-TNF effects)
   Description: Rarely used; evidence minimal in APP.
   Dosage: 400 mg TID.
   Mechanism: Rheology improvement; cytokine modulation.

6. Stem-cell–derived exosome cosmetics (experimental)
   Description: Cosmetic market products without APP evidence; not recommended outside research.
   Dosage: Topical.
   Mechanism: Putative paracrine signaling.

(Emphasis: these are not standard of care for APP and should be avoided outside trials or expert centers.) NCBI

---

Surgeries/Procedures

1. Fractional Laser Resurfacing (non-ablative preferred first)
   Procedure: Series of sessions to stimulate dermal remodeling.
   Why done: To reduce the look of shallow depressions and blend color when disease is stable. NCBI

2. Ablative Fractional Laser (CO₂/Er:YAG) — second line
   Procedure: Deeper columns of ablation/remodeling.
   Why done: Considered only for very selected, stable lesions with significant atrophy; higher PIH risk. NCBI

3. Targeted Pigment Lasers
   Procedure: Q-switched/picosecond lasers.
   Why done: Focus on hyperpigmentation contrast under expert care. NCBI

4. Dermal Fillers (Hyaluronic Acid) — focal depressions
   Procedure: Micro-aliquots into the atrophic plane.
   Why done: Immediate contour improvement when stable and cosmetically impactful. NCBI

5. Surgical Excision/Grafting — rarely
   Procedure: Remove small, isolated lesions or resurface with graft/partial closure.
   Why done: Uncommon; reserved for highly focal, distressing areas after stability confirmed. NCBI

---

Preventions (realistic, supportive)

1. Early evaluation if new atrophic patches appear. NCBI

2. Sun-smart behavior to limit contrast. DermNet®

3. Prompt treatment of suspected Lyme by local guidelines where exposure risk exists. PubMed

4. Avoid unsupervised strong topicals that can thin skin more. Frontiers

5. Moisturize daily to optimize surface optics. NCBI

6. Monitor with photos to catch change early. NCBI

7. Protect procedures in darker skin (test spots, conservative settings). NCBI

8. Address anxiety/body-image to prevent avoidance cycles. NCBI

9. Review meds that cause photosensitivity if doing light therapy (e.g., doxycycline). Yonsei University

10. Regular dermatologist follow-up in progressive/atypical cases. NCBI

---

When to See a Doctor

See a dermatologist if: (a) new sunken, sharply edged brown patches appear; (b) a known patch spreads rapidly, becomes firm, painful, or develops a lilac rim (morphea concern); (c) you live in/visited a Lyme-endemic area and have compatible symptoms or positive tests; (d) you are considering lasers/fillers/phototherapy; or (e) appearance is hurting your quality of life. DermNet®+1

---

Things to Eat and to Avoid

What to eat (supportive, not curative):

1. Colorful fruits/vegetables for antioxidants (berries, leafy greens).

2. Protein sources for skin repair (fish, legumes, eggs if tolerated).

3. Omega-3 rich fish (salmon, sardines).

4. Nuts/seeds (walnuts, flax, chia).

5. Whole grains (oats, brown rice).

6. Fermented foods (yogurt, kefir) if tolerated.

7. Adequate hydration daily.

8. Vitamin C sources (citrus, kiwi).

9. Foods with polyphenols (green tea, cocoa in moderation).

10. Vitamin D-rich foods (fortified milk, oily fish) especially with rigorous sun protection.

What to limit/avoid (for skin balance and pigment stability):

1. Excess alcohol (dehydrates skin).

2. Smoking/vaping (impairs collagen).

3. High-sugar ultra-processed foods (glycation of collagen).

4. Crash dieting (nutrient deficiencies).

5. Unverified “skin lightening” supplements.

6. High-dose single-nutrient mega-supplementation without labs.

7. Tanning beds/intentional sunbathing.

8. Harsh scrubs/acids on lesions.

9. DIY steroid use.

10. Overlapping photosensitizing herbs with light therapy (e.g., St. John’s wort). (Diet advice is supportive general dermatology wellness; APP-specific diet trials don’t exist.) NCBI

---

Frequently Asked Questions (FAQ)

1) Is APP dangerous or cancerous?
No. It is benign and mainly affects appearance. Internal organs are not involved. DermNet®

2) Will APP spread?
Some patches slowly expand for months to years, then often stabilize. Regular photos help monitor change. NCBI

3) How is APP different from morphea?
APP is non-indurated dermal atrophy with a cliff-drop edge; morphea is typically firmer/indurated with inflammatory phases. There is overlap; some see APP on the morphea spectrum. NCBI+1

4) Do I need a biopsy?
Not always. Classic lesions can be diagnosed clinically; biopsy helps when features are atypical or progressive. NCBI

5) Is there a cure?
There is no single proven cure. Care focuses on cosmetic blending and, if active overlap is suspected, anti-inflammatory or phototherapy approaches. NCBI

6) Do antibiotics help?
Only in selected patients with evidence or risk of Borrelia. Studies show improvement in subsets but the association is controversial. Don’t take antibiotics without medical advice. PubMed+1

7) Can light therapy help?
UVA1 or NB-UVB/excimer can help morphea-spectrum disease and might help certain APP-like, active cases, but evidence is limited. Frontiers+1

8) Will steroid creams thin my skin more?
Potent steroids can thin the epidermis if overused. Short, supervised courses may help when activity is suspected; otherwise, avoid prolonged use. Frontiers

9) Are lasers safe?
When lesions are stable and performed by experts, lasers can help color/texture, but risks include post-inflammatory pigment change, especially in skin of color. Test spots and conservative settings matter. NCBI

10) Can fillers fix the dents?
Sometimes small hyaluronic acid fillers improve focal depressions in stable lesions. It is off-label and requires an experienced injector. NCBI

11) Does APP itch or hurt?
Usually no; lesions are typically asymptomatic. Pain or firmness suggests reevaluation. DermNet®

12) Is APP common in children?
It can occur in youths and young adults; many cases are reported in the second and third decades. Leprosy Review

13) Can APP appear on the face or limbs?
Most often on the back/trunk, but other sites can occur. PubMed

14) What does the pathology show?
Thinned dermis, sometimes flattened rete ridges, fragmented collagen, mild perivascular lymphocytes, and pigment incontinence; sclerosis is usually absent. Lippincott Journals+1

15) Will it come back after improvement?
Lesions often become stable; color may fade slowly. Activity recurrence is uncommon but possible, especially if truly on the morphea spectrum. Follow-up is sensible. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 28, 2025.

PDF Documents For This Disease Condition References